BWI: Sun Pharma Announces USFDA Approval for Generic Wellbutrin SR® Extended Release Tablets

Press release from Business Wire India
Source: Sun Pharmaceuticals Industries Ltd
Thursday, April 08, 2010 08:02 AM IST (02:32 AM GMT)
Editors: General: Consumer interest, Economy; Business: Financial Analyst, Healthcare, biotechnology & pharmaceutical, Law firms; Healthcare
--------------------------------------------------
Sun Pharma Announces USFDA Approval for Generic Wellbutrin SR® Extended Release Tablets


Mumbai, Maharashtra, India, Thursday, April 08, 2010 -- (Business Wire India) -- Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of GlaxoSmithKline's Wellbutrin SR® Extended Release tablets.

These generic Bupropion Hydrochloride Extended Release tablets are equivalent to GlaxoSmithKline's Wellbutrin SR® Extended Release tablets and includes three strengths: 100 mg, 150 mg and 200 mg. These strengths of generic Bupropion Hydrochloride Extended Release tablets have a combined annual sale of approximately $ 300 million in the US.

Bupropion Hydrochloride (SR) Extended Release tablets are indicated for the treatment of major depressive disorder.

Wellbutrin SR® is a registered trademark of GlaxoSmithKline.

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.



CONTACT DETAILS
Uday Baldota, Sun Pharmaceuticals Industries Ltd, +91 22 6645 5645, Xtn 605, +91 22 66455605, Mobile: +91 98670 10529, uday.baldota@sunpharma.com
Mira Desai, Sun Pharmaceuticals Industries Ltd, +91 22 6645 5645, Xtn 606, +91 22 66455606, Mobile: +91 98219 23797, mira.desai@sunpharma.com

KEYWORDS
CONSUMER, ECONOMY, Financial Analyst, HEALTHCARE, LAW FIRMS, HEALTHCARE, SUNPHARMA.BO, SUNPHARMA .NS

If you wish to change your Business Wire India selection please click on this link http://www.businesswireindia.com/media/news.asp and use your personal username and password to login.

Submit your press release at http://www.businesswireindia.com